Why are medicine shortages still a systemic issue?

U.S. prescription drug shortages keep improving, but persist

A new STAT+ analysis highlights that U.S. medicine shortages remain a systemic problem even as the situation improves. The number of prescription drug shortages in the U.S. fell by 23% last year, marking the second consecutive year of declines.

Importantly for readers, the analysis frames this as progress without resolution: the count reportedly reached the lowest level since 2017. That suggests supply and demand dynamics are shifting in a better direction, but the underlying drivers of shortages have not been eliminated.

What the decline signals

A multi-year drop typically means at least some combination of factors has eased—such as fewer disruptions at manufacturing sites, improved replenishment of product supply, or stabilizing demand pressures in certain therapy areas. The “systemic” label, however, indicates that shortages are not just caused by one-off events.

Why it still matters

Drug shortages are consequential because they can force clinicians to change regimens, delay care, or switch patients to alternatives that may not be equivalent for every situation. Even when the overall number declines, shortages can remain concentrated in specific medications that are difficult to replace.

Bottom line

The key takeaway is that shortages are trending downward—but they still represent an enduring vulnerability in the U.S. drug supply chain. Policymakers and industry leaders will likely continue working to address root causes, aiming not just for temporary improvements but sustained reduction.